TY - JOUR
T1 - Systematic review of targeted extracellular vesicles for drug delivery
T2 - Considerations on methodological and biological heterogeneity
AU - Gudbergsson, Johann Mar
AU - Jønsson, Katrine
AU - Simonsen, Jens Bæk
AU - Johnsen, Kasper Bendix
PY - 2019/7/28
Y1 - 2019/7/28
N2 - The idea of using extracellular vesicles (EVs) for targeted drug delivery was first introduced in 2011 and has since then gained increasing attention as promising new candidates in the field. Targeting EVs to areas of disease can be achieved through a complex process of designing and inserting a targeting ligand to the surface of the EVs. Although this can be obtained via chemical conjugation, the most important strategy has been to transfect or modulate the EV-producing cell to endow the EVs with the desired targeting capabilities. However, since EVs are harvested from biological sources, their composition is highly heterogeneous, which makes it difficult to control the purity and quality of the resulting EV-based drug delivery vehicles. In this review, we present a detailed account of EVs in targeted drug delivery based on a systematic literature search. We discuss the potential advantages of EVs compared to synthetic lipid-based nanocarriers, and the methodological and biological limitations associated with their use as targeted drug delivery vehicles.
AB - The idea of using extracellular vesicles (EVs) for targeted drug delivery was first introduced in 2011 and has since then gained increasing attention as promising new candidates in the field. Targeting EVs to areas of disease can be achieved through a complex process of designing and inserting a targeting ligand to the surface of the EVs. Although this can be obtained via chemical conjugation, the most important strategy has been to transfect or modulate the EV-producing cell to endow the EVs with the desired targeting capabilities. However, since EVs are harvested from biological sources, their composition is highly heterogeneous, which makes it difficult to control the purity and quality of the resulting EV-based drug delivery vehicles. In this review, we present a detailed account of EVs in targeted drug delivery based on a systematic literature search. We discuss the potential advantages of EVs compared to synthetic lipid-based nanocarriers, and the methodological and biological limitations associated with their use as targeted drug delivery vehicles.
KW - Drug delivery
KW - Exosomes
KW - Extracellular vesicles
KW - Kinetics
KW - Liposomes
KW - Microvesicles
KW - Nanoparticles
KW - Pharmacokinetics
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=85066948675&partnerID=8YFLogxK
U2 - 10.1016/j.jconrel.2019.06.006
DO - 10.1016/j.jconrel.2019.06.006
M3 - Review article
SN - 0168-3659
VL - 306
SP - 108
EP - 120
JO - Journal of Controlled Release
JF - Journal of Controlled Release
ER -